Production (Stage)
Avalo Therapeutics, Inc.
AVTX
$3.75
-$0.16-4.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 73.01M | -35.13M | -7.96M | -36.22M | -142.88M |
| Total Depreciation and Amortization | 270.00K | 169.00K | 144.00K | 151.00K | 159.00K |
| Total Amortization of Deferred Charges | -- | -- | 0.00 | 1.13M | 1.48M |
| Total Other Non-Cash Items | -123.35M | -9.39M | -24.95M | 9.00M | 123.39M |
| Change in Net Operating Assets | -2.25M | -4.71M | -4.01M | -6.14M | -8.98M |
| Cash from Operations | -52.31M | -49.06M | -36.78M | -32.09M | -26.83M |
| Capital Expenditure | -- | -- | 0.00 | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 0.00 | 0.00 |
| Cash Acquisitions | 0.00 | 356.00K | 356.00K | 356.00K | 356.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00 | 356.00K | 356.00K | 356.00K | 356.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00 | -15.24M | -21.24M |
| Issuance of Common Stock | 69.44M | 185.07M | 115.63M | 141.57M | 148.16M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.21M | -9.22M | -7.49M | -7.49M | -7.01M |
| Cash from Financing | 67.24M | 175.85M | 108.14M | 118.84M | 119.91M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.93M | 127.15M | 71.72M | 87.11M | 93.43M |